Compare EP & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EP | LONA |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.9M | 90.4M |
| IPO Year | 1996 | N/A |
| Metric | EP | LONA |
|---|---|---|
| Price | $2.68 | $8.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 66.0K | 36.3K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $34,203,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.41 | $4.21 |
| 52 Week High | $5.80 | $14.21 |
| Indicator | EP | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 49.17 | 35.99 |
| Support Level | N/A | $8.10 |
| Resistance Level | $2.92 | $11.44 |
| Average True Range (ATR) | 0.21 | 0.93 |
| MACD | 0.02 | -0.23 |
| Stochastic Oscillator | 63.64 | 0.60 |
Empire Petroleum Corp is a conventional oil and natural gas producer with a main focus in the United States onshore. The company possesses long-life, mature, producing assets with slow decline profiles in the Permian Basin, Bakken region and central Gulf Coast region, in the states of New Mexico, North Dakota, Montana, Louisiana and Texas. It has production from operated and non-operated wells in Lea County in New Mexico, Bottineau, Renville, Burke, and McKenzie Counties in North Dakota, Richland County in Montana, St. Landry, Beauregard Parishes in Louisiana and Houston, Leon and Madison Counties in Texas. The Company operates as one operating segment and one reportable segment which is engaged in the exploration, development, and production of oil, gas, and NGLs.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.